Antipsychotic Medications and Weight Management

Introduction to Antipsychotic-Induced Weight Gain

Aripiprazole has a lower risk for weight gain compared to other antipsychotics, such as olanzapine, clozapine, and quetiapine, due to its partial agonist effect at 5-HT2C receptors and lower histamine H1 receptor antagonism 1

Antipsychotic-induced weight gain is partially mediated through antagonism of hypothalamic H1 receptors, with medications having stronger H1 receptor antagonism generally causing more weight gain 1

Aripiprazole, lurasidone, and ziprasidone are considered to have a lower risk for weight gain, while quetiapine, olanzapine, and clozapine are associated with a higher risk, according to the American Gastroenterological Association 1

Regular weight monitoring is essential, particularly in pediatric patients, patients taking high-serotonergic antidepressants, and treatment-naïve individuals, with weight management programs recommended from the start of medication initiation, especially in young people 1
The American Diabetes Association recommends screening for prediabetes or diabetes at baseline, 12-16 weeks after initiation, and annually thereafter for patients starting quetiapine, with a high strength of evidence 2
For patients with metabolic risk factors, considering alternative antipsychotics like lurasidone, ziprasidone, or aripiprazole is suggested, with a moderate level of evidence, according to the American Gastroenterological Association 1
Regular metabolic monitoring is recommended for patients on quetiapine, with a high level of evidence 1